Investor Presentaiton

Strong business momentum Diversified portfolio growth 2 Efficient compounding engine Sustainable long-term growth Recently launched products amplify and diversify growth Adjusted Cash Receipts (1) ("top-line") Key growth drivers Therapy Marketer(s) 2025e market position (2) 2025e sales(2) Erleada J&J #2 for prostate cancer ~$3bn Evrysdi Roche #1 for SMA ~$2bn CAGR: ~70% $350-450m Nurtec™ODT Biohaven /Pfizer #1 for migraine ~$2bn Gilead TRODELVY #1 for 2nd line+ triple negative breast cancer ~$2bn Emgality. Lilly #5 for migraine ~$1bn CRYSVITA Kyowa Kirin Ultragenyx #1 for X-linked (3) hypophosphatemia ~$1bn #1 oral therapy orladeyo BioCryst for HAE <$1bn ~$30m #1 for primary hyperoxaluria OXLUMO Alnylam type 1 <$1bn 2020 2025e SMA: Spinal muscular atrophy; HAE: Hereditary angioedema ROYALTY PHARMA 1. See slide 114 for definitions and factors that may impact the achievement of our growth outlook. 2. Market positions based on Evaluate Pharma sales data as of May 9, 2022. Consensus sales estimates from Visible Alpha as of May 9, 2022. 3. Represents worldwide sales. Royalty Pharma only receives royalties on sales from Europe, the Middle East, and Africa. 91

View entire presentation